中山大学学报（医学科学版）2011，Vol.32Issue(3)：383-388,420,7.
乳腺癌分子分型在新辅助化疗疗效和预后中的预测作用
Predictive Role of Breast Cancer Molecular Subtype in Response and Outcome of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
吴建南 1李顺荣 1顾然 1萧俏珍 1苏逢锡1
作者信息
- 1. 中山大学孙逸仙纪念医院乳腺肿瘤医学部，广东广州510120
- 折叠
摘要
Abstract
[Objective] To investigate the predictive role of breast cancer molecular subtype in the response and outcome of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin chemotherapy. [ Methods ]Two hundred and forty-four patients treated with neoadjuvant chemotherapy were included in this retrospective study. Molecular subtypes were constructed from immunohistochemical results of estrogen receptor (ER), progesterone receptor (PR) and HER2 status, which were classified as Luminal, HER2 positive and Basal-like subtype. [Results] Among all 244 cases, 167 (68.4%) were Luminal subtype, 43(17.6%) were HER2 positive subtype and 34 (13.9%) were Basal-like subtype. Compared with Luminal subtype, the pathological complete response rates of patients with basal-like and HER2 positive subtype were 29.4% and 25.6%, respectively, which were significantly higher than that of patients with Luminal subtype(P - 0.011). Patients with Basal-like and HER2 positive subtype especially for those with residual disease after chemotherapy had decreased 5-years disease-free survival ( DFS) compared with those with Luminal subtype (P < 0.05). And similarly, patients with Basal-like and HER2 positive subtype especially for those with residual disease after chemotherapy had decreased 5-year overall survival (OS) compared with those with Luminal subtype (P < 0.05). The 5-year DFS and OS of patients who achieve pathological complete response (pCR) were significantly higher than that of patients with residual disease after chemotherapy(P < 0.001 ,P = 0.003, respectively). [Conclusion] Molecular subtype can predict the response of breast cancer patients treated with neoadjuvant chemotherapy. Compared with luminal subtype, patients of HER2 positive or basal-like subtype had increased pCR rates, but were associated with significantly worse survival.关键词
乳腺癌/分子分型/新辅助化疗/预后Key words
breast cancer/ molecular subtype/ neoadjuvant chemotherapy/ prognosis分类
医药卫生引用本文复制引用
吴建南,李顺荣,顾然,萧俏珍,苏逢锡..乳腺癌分子分型在新辅助化疗疗效和预后中的预测作用[J].中山大学学报（医学科学版）,2011,32(3):383-388,420,7.
